Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Loris De Cecco

Showing results (151-160 of 169) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory AnalysisSara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, et al.
Cellular Oncology (Dordrecht, Netherlands)|November 19, 2020
AKR1C3 is a biomarker and druggable target for oropharyngeal tumorsCaterina Peraldo-Neia, Paola Ostano, Maurizia Mello-Grand, et al.
Cancer Medicine|December 18, 2021
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO studySara Pizzamiglio, Giulia Cosentino, Chiara M Ciniselli, et al.
Cancers|August 27, 2021
Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is RecommendedMarta Giussani, Chiara Maura Ciniselli, Loris De Cecco, et al.
Journal of Neuro-Oncology|May 17, 2018
Correction to: Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhoodMaura Massimino, Veronica Biassoni, Rosalba Miceli, et al.
Journal of Neuro-Oncology|April 4, 2014
Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhoodMaura Massimino, Veronica Biassoni, Rosalba Miceli, et al.
Molecular Oncology|November 24, 2021
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trialTiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2019
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO studySerena Di Cosimo, Tiziana Triulzi, Sara Pizzamiglio, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 11, 2023
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trialLuca Forlani, Loris De Cecco, Vittorio Simeon, et al.
NPJ Precision Oncology|November 17, 2025
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trialEliana Pivetta, Vincenzo Canzonieri, Marina Bagnoli, et al.
Pageof 17

Showing results (151-160 of 169) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory AnalysisSara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, et al.
Cellular Oncology (Dordrecht, Netherlands)|November 19, 2020
AKR1C3 is a biomarker and druggable target for oropharyngeal tumorsCaterina Peraldo-Neia, Paola Ostano, Maurizia Mello-Grand, et al.
Cancer Medicine|December 18, 2021
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO studySara Pizzamiglio, Giulia Cosentino, Chiara M Ciniselli, et al.
Cancers|August 27, 2021
Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is RecommendedMarta Giussani, Chiara Maura Ciniselli, Loris De Cecco, et al.
Journal of Neuro-Oncology|May 17, 2018
Correction to: Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhoodMaura Massimino, Veronica Biassoni, Rosalba Miceli, et al.
Journal of Neuro-Oncology|April 4, 2014
Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhoodMaura Massimino, Veronica Biassoni, Rosalba Miceli, et al.
Molecular Oncology|November 24, 2021
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trialTiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2019
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO studySerena Di Cosimo, Tiziana Triulzi, Sara Pizzamiglio, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 11, 2023
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trialLuca Forlani, Loris De Cecco, Vittorio Simeon, et al.
NPJ Precision Oncology|November 17, 2025
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trialEliana Pivetta, Vincenzo Canzonieri, Marina Bagnoli, et al.
Pageof 17